Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital

Niagen Bioscience (NASDAQ:NAGE) was upgraded by research analysts at Freedom Capital to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

NAGE has been the subject of a number of other reports. Canaccord Genuity Group lowered their target price on Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. HC Wainwright restated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, July 1st. Wall Street Zen downgraded shares of Niagen Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $10.50.

Niagen Bioscience Trading Down 2.3%

Shares of NAGE stock opened at $3.37 on Monday. The stock has a market capitalization of $268.39 million, a price-to-earnings ratio of 16.05 and a beta of 2.09. Niagen Bioscience has a 12-month low of $3.17 and a 12-month high of $12.41. The stock’s 50-day moving average price is $3.70 and its 200-day moving average price is $4.79.

Niagen Bioscience (NASDAQ:NAGE) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $31.47 million during the quarter. Niagen Bioscience had a return on equity of 22.68% and a net margin of 14.29%. As a group, research analysts predict that Niagen Bioscience will post 0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Niagen Bioscience

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in Niagen Bioscience by 188.9% during the 1st quarter. Bank of America Corp DE now owns 304,718 shares of the company’s stock valued at $1,344,000 after purchasing an additional 199,227 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Niagen Bioscience by 90.0% in the first quarter. Quantinno Capital Management LP now owns 50,946 shares of the company’s stock worth $225,000 after purchasing an additional 24,135 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after purchasing an additional 414,725 shares during the last quarter. Teton Advisors LLC lifted its stake in Niagen Bioscience by 20.0% in the first quarter. Teton Advisors LLC now owns 30,000 shares of the company’s stock worth $132,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Gabelli Funds LLC boosted its position in shares of Niagen Bioscience by 5.2% during the first quarter. Gabelli Funds LLC now owns 214,685 shares of the company’s stock valued at $947,000 after buying an additional 10,685 shares during the period. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.